HRP20100370T1 - Himerni rekombinantni antigeni toxoplasma gondii - Google Patents
Himerni rekombinantni antigeni toxoplasma gondii Download PDFInfo
- Publication number
- HRP20100370T1 HRP20100370T1 HR20100370T HRP20100370T HRP20100370T1 HR P20100370 T1 HRP20100370 T1 HR P20100370T1 HR 20100370 T HR20100370 T HR 20100370T HR P20100370 T HRP20100370 T HR P20100370T HR P20100370 T1 HRP20100370 T1 HR P20100370T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- nucleotide sequence
- fact
- chimeric
- chimeric antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 17
- 102000036639 antigens Human genes 0.000 title claims abstract 17
- 108091007433 antigens Proteins 0.000 title claims abstract 17
- 241000223997 Toxoplasma gondii Species 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 201000005485 Toxoplasmosis Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 201000007045 Congenital toxoplasmosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Himerni rekombinantni antigen koji sadrži fuziju bar tri antigena regije Toxoplasm-e gondii, naznačen time, što tri različita antigena regije imaju amino-kiselinsku sekvencu odabranu iz grupe koja se sastoji od: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12. Patent sadrži još 26 patentnih zahtjeva.
Claims (27)
1. Himerni rekombinantni antigen koji sadrži fuziju bar tri antigena regije Toxoplasm-e gondii, naznačen time, što tri različita antigena regije imaju amino-kiselinsku sekvencu odabranu iz grupe koja se sastoji od: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12.
2. Himerni antigen iz zahtjeva 1, naznačen time, što uključuje amino-kiselinsku sekvencu SEQ ID NO: 28.
3. Himerni antigen prema zahtjevu 1, naznačen time, što uključuje amino-kiselinsku sekvencu SEQ ID NO: 30.
4. Himerni antigen prema zahtjevu 1, naznačen time, što uključuje amino-kiselinsku sekvencu SEQ ID NO: 32.
5. Nukleotidna sekvenca, naznačena time, što kodira himerni antigen prema nekom od prethodnih zahtjeva.
6. Nukleotidna sekvenca prema zahtjevu 5, naznačena time, što uključuje bar tri različite nukleotidne sekvence odabrane iz grupe koja sadrži: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 i SEQ ID NO: 11.
7. Nukleotidna sekvenca prema zahtjevima 5 ili 6, naznačena time, što uključuje nukleotidnu sekvencu SEQ ID NO: 27.
8. Nukleotidna sekvenca prema zahtjevima 5 ili 6, naznačena time, što uključuje nukleotidnu sekvencu SEQ ID NO: 29.
9. Nukleotidna sekvenca prema zahtjevima 5 ili 6, naznačena time, što uključuje nukleotidnu sekvencu SEQ ID NO: 31.
10. Nukleotidna sekvenca, naznačena time, što se hibridizira sa nekom od sekvenci prema zahtjevima 5 do 9, pod strogim uvjetima hibridizacije.
11. Himerni rekombinantni antigen, naznačen time, što ga kodira nukleotidna sekvenca iz zahtjeva 10.
12. Nukleotidna sekvenca iz nekog od zahtjeva 5 do 10, naznačena time, što je to sekvenca DNK.
13. Vektor, naznačen time, što uključuje DNK sekvencu iz zahtjeva 12.
14. Stanica-domaćin, naznačena time, što je transformirana vektorom iz zahtjeva 13.
15. Postupak za proizvodnju himernog antigena prema nekom od zahtjeva 1 do 4 ili 11, naznačen time, što uključuje kultiviranje stanice-domaćina iz zahtjeva 14 i izoliranje željenog proizvoda.
16. Uporaba himernih antigena prema nekom od zahtjeva 1 do 4 ili 11, naznačena time, što se upotrebljavaju kao aktivna sredstva za in vitro dijagnosticiranje infekcija Toxoplasma-om gondii.
17. Uporaba prema zahtjevu 16, naznačena time, što se odnosi na dijagnosticiranje kongenitalne toksoplazmoze kod djece.
18. Upotreba prema zahtjevu 16, naznačena time, što se odnosi na dijagnosticiranje vremena infekcije.
19. Kitovi za dijagnosticiranje infekcije Toxoplasma-om gondii, naznačeni time, što sadrže bar jedan himerni antigen prema nekom od zahtjeva 1 do 4 ili 11.
20. Kitovi za dijagnosticiranje akutne ili kronične infekcije Toxoplasma-om gondii, naznačeni time, što sadrže bar jedan himerni antigen prema nekom od zahtjeva 1 do 4 ili 11.
21. Himerni antigeni prema nekom od zahtjeva 1 do 4 ili 11, naznačeni time, što se koriste kao lijekovi.
22. Uporaba himernih antigena iz nekog od zahtjeva 1 do 4 ili 11, naznačena time, što se upotrebljavaju kao aktivni sastojci za pripremanje lijekova za prevenciju ili liječenje infekcija Toxoplasma-om gondii.
23. Nukleotidna sekvenca iz nekog od zahtjeva 5 do 10, naznačena time, što se koristi kao lijek.
24. Uporaba nukleotidne sekvence iz nekog od zahtjeva 5 do 10, naznačena time, što se upotrebljava za pripremanje lijekova korisnih u liječenju ili prevenciji infekcija Toxoplasma-om gondii.
25. Farmaceutska smjesa, posebno u obliku injekcije, naznačena time, što sadrži bar jedan himerni antigen iz nekog od zahtjeva 1 do 4 ili 11.
26. Farmaceutska smjesa, posebno u obliku injekcije, naznačena time, što sadrži bar jednu nukleotidnu sekvencu prema nekom od zahtjeva 5 do 10.
27. Smjesa prema zahtjevu 25 ili 26, naznačena time, što je pogodna za primjenu kod ljudi i/ili u veterini.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05005065 | 2005-03-08 | ||
| PCT/EP2006/001760 WO2006094665A1 (en) | 2005-03-08 | 2006-02-27 | Chimeric recombinant antigens of toxoplasma gondii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100370T1 true HRP20100370T1 (hr) | 2010-08-31 |
Family
ID=34934134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100370T HRP20100370T1 (hr) | 2005-03-08 | 2010-07-01 | Himerni rekombinantni antigeni toxoplasma gondii |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US7790187B2 (hr) |
| EP (1) | EP1856159B1 (hr) |
| JP (1) | JP2008535481A (hr) |
| KR (1) | KR20080003330A (hr) |
| CN (1) | CN101137674A (hr) |
| AT (1) | ATE463515T1 (hr) |
| AU (1) | AU2006222315A1 (hr) |
| BR (1) | BRPI0608342A2 (hr) |
| CA (1) | CA2599620A1 (hr) |
| CY (1) | CY1110157T1 (hr) |
| DE (1) | DE602006013428D1 (hr) |
| DK (1) | DK1856159T3 (hr) |
| EA (1) | EA013349B1 (hr) |
| ES (1) | ES2342971T3 (hr) |
| HR (1) | HRP20100370T1 (hr) |
| IL (1) | IL184845A (hr) |
| MX (1) | MX2007009524A (hr) |
| PL (1) | PL1856159T3 (hr) |
| PT (1) | PT1856159E (hr) |
| RS (1) | RS51327B (hr) |
| SI (1) | SI1856159T1 (hr) |
| WO (1) | WO2006094665A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009003497A1 (en) * | 2007-06-29 | 2009-01-08 | Prionics Ag | Diagnostic composition and method for the detection of a trichinella infection |
| EP2654782A4 (en) * | 2010-12-23 | 2015-03-25 | Immport Therapeutics Inc | PROCESSES AND COMPOSITIONS FROM PROTEIN ANTIGEN FOR THE DIAGNOSIS AND TREATMENT OF TOXOPLASMA GONDII INFECTIONS AND TOXOPLASMOSIS |
| CN102288768A (zh) * | 2011-09-19 | 2011-12-21 | 厦门市湖里区妇幼保健院 | 弓形虫IgG抗体免疫印迹试剂盒及其制备方法 |
| CN102492696B (zh) * | 2011-12-13 | 2014-01-29 | 北京英诺特生物技术有限公司 | 一种重组弓形虫蛋白及其应用 |
| CN103235119B (zh) * | 2013-04-11 | 2015-09-16 | 南京农业大学 | 一种用于弓形虫感染的诊断抗原的应用 |
| CN103251960B (zh) * | 2013-05-27 | 2014-08-13 | 山东大学 | 用于预防人或动物慢性弓形虫病的dna疫苗 |
| CN104152466A (zh) * | 2014-04-04 | 2014-11-19 | 中国农业科学院兰州兽医研究所 | 一种用于弓形虫感染预防的疫苗和制备方法及其应用 |
| WO2016046321A1 (en) * | 2014-09-25 | 2016-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating cancer and infectious diseases |
| CN105759030B (zh) * | 2016-03-15 | 2018-01-02 | 中国农业大学 | 一种检测弓形虫抗体的胶体金试纸条 |
| CN106153894A (zh) * | 2016-08-12 | 2016-11-23 | 江苏泽成生物技术有限公司 | 一种测定弓形虫IgM抗体的检测试剂盒及其检测方法 |
| CN108265070B (zh) * | 2016-12-30 | 2022-07-26 | 中国农业科学院上海兽医研究所 | 一种特异性的检测弓形虫的方法 |
| CN107253983A (zh) * | 2017-06-28 | 2017-10-17 | 潍坊汉唐生物工程有限公司 | 一种检测弓形虫抗体的重组蛋白组合物及其制备方法 |
| CN108165569A (zh) * | 2017-11-10 | 2018-06-15 | 江苏省血吸虫病防治研究所 | 一种快速检测弓形虫的重组蛋白及其制备方法和应用 |
| US11911464B2 (en) | 2018-09-14 | 2024-02-27 | Prommune, Inc. | Anti-parasitic immunological compositions |
| CN109369796A (zh) * | 2018-09-27 | 2019-02-22 | 华中农业大学 | 一种检测羊弓形虫IgG抗体的酶联免疫方法 |
| CN110540602B (zh) * | 2019-08-28 | 2023-02-14 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种弓形虫表面抗原gra1和gra7重组蛋白胶体金试纸条 |
| CN110818787B (zh) * | 2019-12-04 | 2023-08-04 | 南京医科大学 | 一种增加Ly6C+巨噬细胞的抗原及其应用 |
| CN111116726A (zh) * | 2020-01-14 | 2020-05-08 | 中国农业科学院北京畜牧兽医研究所 | 用于检测弓形虫的重组蛋白及其编码基因 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2226468A1 (en) | 1973-04-18 | 1974-11-15 | Merieux Bd | Toxoplasma antigens - as agents for detecting toxoplasmosis by direct agglutination |
| SU533376A1 (ru) | 1973-08-31 | 1976-10-30 | Научно-исследовательский ветеринарный институт | Способ получени токсоплазменного антигена |
| JPS5444016A (en) | 1977-09-13 | 1979-04-07 | Nippon Touketsu Kansou Kenkiyu | Latex coagulation and reaction reagent for detecting toxoplasma antibody and production thereof |
| DE3940598A1 (de) | 1989-12-08 | 1991-06-13 | Behringwerke Ag | Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung |
| FR2518407A1 (fr) | 1981-12-17 | 1983-06-24 | Merieux Inst | Nouvel antigene pour la recherche de l'immunite toxoplasmique et son procede de preparation |
| US6265176B1 (en) * | 1985-10-29 | 2001-07-24 | Cordis Corporation | Dot immunoassay on plastic sheets |
| IT1196817B (it) | 1986-12-03 | 1988-11-25 | Consiglio Nazionale Ricerche | Procedimento per l'ottenimento di una preparazione di antigene toxoplasmico insolubile corredo diagnostico comprendente tale preparazione e saggio diagnostico che la utilizza |
| FR2618680B1 (fr) | 1987-07-31 | 1990-05-11 | Pasteur Institut | Antigenes d'excretion-secretion specifiques de toxoplasma gondii, leurs produits d'expression, leur procede d'obtention et leurs applications diagnostiques et prophylactiques |
| FR2625099B1 (fr) | 1987-12-24 | 1991-06-14 | Transgene Sa | Proteines et leur procede de preparation, sequences d'adn, anticorps et leur application, poxvirus, cellules transformees ou infectees et compositions pharmaceutiques utiles dans la prevention de la toxoplasmose |
| US4877726A (en) * | 1988-03-02 | 1989-10-31 | Research Institute Of Palo Alto Medical Foundation | Method for the detection of acute-phase toxoplasma infection |
| DE68926658T2 (de) | 1988-03-09 | 1996-11-28 | Univ Leland Stanford Junior | Diagnostische gene zum nachweis von toxoplasmose |
| FR2633309B1 (fr) | 1988-06-24 | 1992-04-24 | Pasteur Institut | Sequence d'adn codant pour la proteine p30 de toxoplasma gondii, produits d'expression de cette sequence, leurs procedes d'obtention et leurs applications |
| JPH02261382A (ja) | 1989-04-03 | 1990-10-24 | Mochida Pharmaceut Co Ltd | トキソプラズマ由来新規ｄｎａ配列およびそれによってコードされる蛋白質 |
| US5215917A (en) * | 1989-11-03 | 1993-06-01 | Research Institute Of Palo Alto Medical Foundation | Nucleotide sequence encoding the Toxoplasma gondii P22 gene |
| US5665542A (en) * | 1989-11-03 | 1997-09-09 | Research Institute Of Palo Alto Medical Foundation | Toxoplasma gondii P28 gene and methods for its use |
| FR2664290B1 (fr) | 1990-07-05 | 1993-01-29 | Centre Nat Rech Scient | Sondes genetiques specifiques de toxoplasma gondii, et leur utilisation pour la detection in vitro de toxoplasma gondii et pour le typage des souches toxoplasmiques. |
| US5578453A (en) | 1990-08-10 | 1996-11-26 | The Flinders University Of South Australia | Cloning and expression of toxoplasma antigens and use of recombinant antigens |
| GB9027728D0 (en) | 1990-12-20 | 1991-02-13 | Smithkline Beecham Biolog | Novel protein |
| FR2692282B1 (fr) * | 1992-06-15 | 1995-07-13 | Pasteur Institut | Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications. |
| WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| FR2702491B1 (fr) | 1993-03-12 | 1995-04-28 | Pasteur Institut | Clonage de gènes codant pour des antigènes d'excrétion-sécrétion P21 et P32 de toxoplasme, préparations de tels antigènes, fragments de ceux-ci et leurs applications. |
| US5976553A (en) * | 1993-11-04 | 1999-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Transfection and genetic manipulations in obligate intracellular parasites |
| FR2722508B1 (fr) | 1994-07-13 | 1996-10-04 | Transgene Sa | Cassette d'expression d'une proteine p30 de toxoplasma gondii |
| EP0710724A2 (en) | 1994-10-06 | 1996-05-08 | Akzo Nobel N.V. | Toxoplasma gondii antigens |
| FR2729960A1 (fr) | 1995-01-30 | 1996-08-02 | Bio Merieux | Polypeptides mimotopes de toxoplasma gondii et applications |
| EP0877809A1 (en) | 1996-01-26 | 1998-11-18 | Innogenetics N.V. | TOXOPLASMA GONDII ANTIGEN Tg20 |
| SE505631C2 (sv) | 1996-08-30 | 1997-09-22 | Scania Cv Ab | Buss med tvärställt bakre drivaggregat |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| JP3831754B2 (ja) | 1997-10-23 | 2006-10-11 | 青才 文江 | トキソプラズマ・ゴンディ抗原、これをコードする核酸並びに該抗原に対する抗体 |
| JP3336275B2 (ja) | 1997-10-23 | 2002-10-21 | 明彦 矢野 | トキソプラズマ・ゴンディ抗原、該抗原に対する抗体及び該抗原又は抗体を用いた免疫測定方法 |
| WO1999032633A1 (en) | 1997-12-19 | 1999-07-01 | Heska Corporation | Toxoplasma gondii proteins, corresponding nucleic acid molecules, and uses thereof |
| US5962654A (en) * | 1998-01-30 | 1999-10-05 | International Business Machines Operation | Alkoxyalkoxides and use to form films |
| UA73718C2 (en) | 1998-05-01 | 2005-09-15 | Schering Plough Ltd | Therapeutic vector expressing foreign dna, coding cat's cd80, cat's cd86, cat's cd28 or cat's ctla-4 and use thereof |
| US6329157B1 (en) * | 1998-05-28 | 2001-12-11 | Abbott Laboratories | Antigen cocktails and uses thereof |
| CA2333598C (en) | 1998-05-28 | 2009-10-13 | Abbott Laboratories | Toxoplasma gondii antigens, p35, and uses thereof |
| AU4510299A (en) | 1998-06-12 | 2000-01-05 | Smithkline Beecham Biologicals (Sa) | Recombinant production of toxoplasma sag1 antigen |
| JP4545869B2 (ja) | 2000-02-23 | 2010-09-15 | 日本ケミファ株式会社 | 多孔性フィルタを用いる生理活性試料物質の測定方法 |
| FR2805466A1 (fr) | 2000-02-25 | 2001-08-31 | Virsol | Utilisation de la proteine mic3 de toxoplasma gondii ou d'un de ses derives en tant qu'agent immunogene ou en tant qu'antigene de vaccination |
| US7176286B2 (en) | 2002-03-21 | 2007-02-13 | Kenton S.R.L. | Antigen fragments for the diagnosis of Toxoplasma gondii |
| US7094879B2 (en) | 2002-10-02 | 2006-08-22 | Abbott Laboratories | Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| CN1194991C (zh) | 2003-05-09 | 2005-03-30 | 李越希 | 重组弓形虫融合蛋白抗原及其制备方法、应用 |
-
2006
- 2006-02-27 AU AU2006222315A patent/AU2006222315A1/en not_active Abandoned
- 2006-02-27 DK DK06723123.3T patent/DK1856159T3/da active
- 2006-02-27 CN CNA2006800068629A patent/CN101137674A/zh active Pending
- 2006-02-27 AT AT06723123T patent/ATE463515T1/de active
- 2006-02-27 SI SI200630701T patent/SI1856159T1/sl unknown
- 2006-02-27 WO PCT/EP2006/001760 patent/WO2006094665A1/en active Application Filing
- 2006-02-27 EA EA200701911A patent/EA013349B1/ru not_active IP Right Cessation
- 2006-02-27 JP JP2008500081A patent/JP2008535481A/ja active Pending
- 2006-02-27 PT PT06723123T patent/PT1856159E/pt unknown
- 2006-02-27 ES ES06723123T patent/ES2342971T3/es active Active
- 2006-02-27 US US11/885,951 patent/US7790187B2/en not_active Expired - Fee Related
- 2006-02-27 KR KR1020077022864A patent/KR20080003330A/ko not_active Application Discontinuation
- 2006-02-27 PL PL06723123T patent/PL1856159T3/pl unknown
- 2006-02-27 EP EP06723123A patent/EP1856159B1/en active Active
- 2006-02-27 BR BRPI0608342-0A patent/BRPI0608342A2/pt not_active IP Right Cessation
- 2006-02-27 DE DE602006013428T patent/DE602006013428D1/de active Active
- 2006-02-27 RS RSP-2010/0283A patent/RS51327B/en unknown
- 2006-02-27 MX MX2007009524A patent/MX2007009524A/es active IP Right Grant
- 2006-02-27 CA CA002599620A patent/CA2599620A1/en not_active Abandoned
-
2007
- 2007-07-26 IL IL184845A patent/IL184845A/en not_active IP Right Cessation
- 2007-09-06 US US11/899,754 patent/US7867503B2/en not_active Expired - Fee Related
-
2010
- 2010-06-25 CY CY20101100583T patent/CY1110157T1/el unknown
- 2010-07-01 US US12/829,367 patent/US20110027810A1/en not_active Abandoned
- 2010-07-01 HR HR20100370T patent/HRP20100370T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI1856159T1 (sl) | 2010-08-31 |
| US7867503B2 (en) | 2011-01-11 |
| MX2007009524A (es) | 2008-03-04 |
| CY1110157T1 (el) | 2015-01-14 |
| PT1856159E (pt) | 2010-06-22 |
| EP1856159A1 (en) | 2007-11-21 |
| DK1856159T3 (da) | 2010-07-05 |
| CN101137674A (zh) | 2008-03-05 |
| EA013349B1 (ru) | 2010-04-30 |
| BRPI0608342A2 (pt) | 2009-12-01 |
| EA200701911A1 (ru) | 2008-02-28 |
| IL184845A (en) | 2011-06-30 |
| AU2006222315A1 (en) | 2006-09-14 |
| US20080280307A1 (en) | 2008-11-13 |
| DE602006013428D1 (de) | 2010-05-20 |
| ES2342971T3 (es) | 2010-07-20 |
| KR20080003330A (ko) | 2008-01-07 |
| IL184845A0 (en) | 2007-12-03 |
| US20090092630A1 (en) | 2009-04-09 |
| EP1856159B1 (en) | 2010-04-07 |
| ATE463515T1 (de) | 2010-04-15 |
| US20110027810A1 (en) | 2011-02-03 |
| JP2008535481A (ja) | 2008-09-04 |
| PL1856159T3 (pl) | 2010-09-30 |
| WO2006094665A1 (en) | 2006-09-14 |
| RS51327B (en) | 2011-02-28 |
| CA2599620A1 (en) | 2006-09-14 |
| US7790187B2 (en) | 2010-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100370T1 (hr) | Himerni rekombinantni antigeni toxoplasma gondii | |
| EP3901260A1 (en) | Coronavirus vaccine | |
| CN105177014B (zh) | Tlr9的合成性激动剂 | |
| DE202021003575U1 (de) | Coronavirus-Vakzine | |
| CN109937253A (zh) | 高纯度rna组合物及其制备方法 | |
| CN105377867A (zh) | I型干扰素的环状二核苷酸诱导 | |
| CN106999577A (zh) | 溶瘤病毒和免疫检查点调节因子组合 | |
| Liu et al. | Surface-displayed porcine IFN-λ3 in Lactobacillus plantarum inhibits porcine enteric coronavirus infection of porcine intestinal epithelial cells | |
| KR20160044566A (ko) | 호흡기 세포융합 바이러스 | |
| HRP20110320T1 (hr) | Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba | |
| CN102066405A (zh) | 用于细胞穿透的超荷电蛋白 | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| EA028304B1 (ru) | Способы конструирования библиотеки белкового каркаса на основе домена фибронектина типа iii (fn3) | |
| SI2280721T1 (en) | IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS | |
| CN106999556A (zh) | 细胞因子诱导的杀伤细胞的双特异性抗体介导的癌症治疗 | |
| CA2380833A1 (en) | Proteins derived from white spot syndrome virus and uses thereof | |
| JP2016504315A5 (hr) | ||
| US20230293652A1 (en) | Immunostimulatory adjuvants | |
| JP6786074B2 (ja) | エキソソーム標的ｄｎａワクチン | |
| Gonzalez-Valdivieso et al. | A DNA vaccine delivery platform based on elastin-like recombinamer nanosystems for rift Valley fever virus | |
| WO2023147092A2 (en) | Coronavirus vaccine | |
| CN108601951A (zh) | 用于治疗的免疫调节组合物 | |
| CN109293782A (zh) | 融合多肽及使用方法 | |
| CN102711817B (zh) | 基于dna疫苗和嵌合体病毒的诱导抗登革热病毒的免疫应答的方法、试剂盒、质粒和组合物 | |
| CA3174599A1 (en) | Improvements in vaccine formulations for medical use |